Bob Yedid

Enalare Therapeutics, Inc. is a clinical-stage biopharmaceutical company that develops novel therapies for patients with life-threatening acute respiratory and critical care conditions, such as community drug overdose, post-operative respiratory depression, and apnea of prematurity. Enalare Therapeutics is based in Princeton, NJ. Enalare maintains rights to its novel compounds and intends to start additional clinical trials with ena-001 for several indications in the near term. The company was founded by Joseph V. Pergolizzi and is currently led by CEO Herm Cukier.

Enalare Therapeutics, Inc. is a clinical-stage biopharmaceutical company that develops novel therapies for patients with life-threatening acute respiratory and critical care conditions, such as community drug overdose, post-operative respiratory depression, and apnea of prematurity. Enalare Therapeutics is based in Princeton, NJ. Enalare maintains rights to its novel compounds and intends to start additional clinical trials with ena-001 for several indications in the near term. The company was founded by Joseph V. Pergolizzi and is currently led by CEO Herm Cukier.

Enalare Therapeutics, Inc. is a clinical-stage biopharmaceutical company that develops novel therapies for patients with life-threatening acute respiratory and critical care conditions, such as community drug overdose, post-operative respiratory depression, and apnea of prematurity. Enalare Therapeutics is based in Princeton, NJ. Enalare maintains rights to its novel compounds and intends to start additional clinical trials with ena-001 for several indications in the near term. The company was founded by Joseph V. Pergolizzi and is currently led by CEO Herm Cukier.

Enalare Therapeutics, Inc. is a clinical-stage biopharmaceutical company that develops novel therapies for patients with life-threatening acute respiratory and critical care conditions, such as community drug overdose, post-operative respiratory depression, and apnea of prematurity. Enalare Therapeutics is based in Princeton, NJ. Enalare maintains rights to its novel compounds and intends to start additional clinical trials with ena-001 for several indications in the near term. The company was founded by Joseph V. Pergolizzi and is currently led by CEO Herm Cukier.

Enalare Therapeutics, Inc. is a clinical-stage biopharmaceutical company that develops novel therapies for patients with life-threatening acute respiratory and critical care conditions, such as community drug overdose, post-operative respiratory depression, and apnea of prematurity. Enalare Therapeutics is based in Princeton, NJ. Enalare maintains rights to its novel compounds and intends to start additional clinical trials with ena-001 for several indications in the near term. The company was founded by Joseph V. Pergolizzi and is currently led by CEO Herm Cukier.